Literature DB >> 25115891

KIR B haplotype donors confer a reduced risk for relapse after haploidentical transplantation in children with ALL.

Lena Oevermann1, Sebastian U Michaelis1, Markus Mezger1, Peter Lang1, Jacek Toporski2, Alice Bertaina3, Marco Zecca4, Lorenzo Moretta5, Franco Locatelli3, Rupert Handgretinger1.   

Abstract

We analyzed the influence of donor killer-cell immunoglobulin-like receptor (KIR) gene haplotypes on the risk for relapse and the probability of event-free survival (EFS) in children with acute lymphoblastic leukemia who received human leukocyte antigen-haploidentical transplantation of ex vivo T-cell-depleted peripheral blood stem cells. The KIR gene haplotype was evaluated in 85 donors, and the KIR B content score was determined in the 63 KIR haplotype B donors. Patients transplanted from a KIR haplotype B donor had a significantly better EFS than those transplanted from a KIR haplotype A donor (50.6% vs 29.5%, respectively; P = .033). Moreover, a high donor KIR B-content score was associated with a significantly reduced risk for relapse (Log-rank test for trend, P = .026). These data indicate that KIR genotyping should be included in the donor selection algorithm for haploidentical transplantation in children with acute lymphoblastic leukemia with the aim of choosing, whenever possible, a KIR haplotype B donor with a high KIR B-content score.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25115891      PMCID: PMC4208288          DOI: 10.1182/blood-2014-03-565069

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  A novel real-time PCR method for KIR genotyping.

Authors:  L G T Alves; R Rajalingam; F Canavez
Journal:  Tissue Antigens       Date:  2009-02

2.  Competing risk analysis using R: an easy guide for clinicians.

Authors:  L Scrucca; A Santucci; F Aversa
Journal:  Bone Marrow Transplant       Date:  2007-06-11       Impact factor: 5.483

3.  Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children.

Authors:  R Handgretinger; T Klingebiel; P Lang; M Schumm; S Neu; A Geiselhart; P Bader; P G Schlegel; J Greil; D Stachel; R J Herzog; D Niethammer
Journal:  Bone Marrow Transplant       Date:  2001-04       Impact factor: 5.483

Review 4.  The extensive polymorphism of KIR genes.

Authors:  Derek Middleton; Faviel Gonzelez
Journal:  Immunology       Date:  2010-01       Impact factor: 7.397

5.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

6.  KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.

Authors:  Sebastian U Michaelis; Markus Mezger; Martin Bornhäuser; Rudolf Trenschel; Gernot Stuhler; Birgit Federmann; Lena Oevermann; Lothar Kanz; Rupert Handgretinger; Wolfgang A Bethge
Journal:  Ann Hematol       Date:  2014-04-26       Impact factor: 3.673

7.  Determinants of antileukemia effects of allogeneic NK cells.

Authors:  Wing Leung; Rekha Iyengar; Victoria Turner; Peter Lang; Peter Bader; Paul Conn; Dietrich Niethammer; Rupert Handgretinger
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

8.  Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments.

Authors:  C Vilches; J Castaño; N Gómez-Lozano; E Estefanía
Journal:  Tissue Antigens       Date:  2007-09-14

9.  Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor.

Authors:  Martin Stern; Loredana Ruggeri; Antonella Mancusi; Maria Ester Bernardo; Claudia de Angelis; Christoph Bucher; Franco Locatelli; Franco Aversa; Andrea Velardi
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

Review 10.  Feasibility and outcome of reduced-intensity conditioning in haploidentical transplantation.

Authors:  Rupert Handgretinger; Xiaohua Chen; Matthias Pfeiffer; Ingo Mueller; Tobias Feuchtinger; Gregory A Hale; Peter Lang
Journal:  Ann N Y Acad Sci       Date:  2007-04-18       Impact factor: 5.691

View more
  49 in total

1.  KIR B or not to be?...that is the question for ALL.

Authors:  Michael R Verneris; Jeffrey S Miller
Journal:  Blood       Date:  2014-10-23       Impact factor: 22.113

2.  Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients.

Authors:  Nicolas J Llosa; Kenneth R Cooke; Allen R Chen; Christopher J Gamper; Orly R Klein; Elias T Zambidis; Brandon Luber; Gary Rosner; Nicholas Siegel; Mary Jo Holuba; Nancy Robey; Masanori Hayashi; Richard J Jones; Ephraim Fuchs; Matthias Holdhoff; David M Loeb; Heather J Symons
Journal:  Biol Blood Marrow Transplant       Date:  2017-08-12       Impact factor: 5.742

Review 3.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 4.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

Review 5.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

Review 6.  Haematological malignancies: at the forefront of immunotherapeutic innovation.

Authors:  Pavan Bachireddy; Ute E Burkhardt; Mohini Rajasagi; Catherine J Wu
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

Review 7.  Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.

Authors:  Marcel van den Brink; Markus Uhrberg; Lorenz Jahn; John F DiPersio; Michael A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

Review 8.  How important is NK alloreactivity and KIR in allogeneic transplantation?

Authors:  Brian C Shaffer; Katharine C Hsu
Journal:  Best Pract Res Clin Haematol       Date:  2016-10-20       Impact factor: 3.020

9.  Central nervous system acute lymphoblastic leukemia: role of natural killer cells.

Authors:  Liron Frishman-Levy; Avishai Shemesh; Allan Bar-Sinai; Chao Ma; Zhenya Ni; Shahar Frenkel; Vera Muench; Hilke Bruckmueller; Christian Vokuhl; Klaus-Michael Debatin; Cornelia Eckert; Martin Stanulla; Martin Schrappe; Kerry S Campbell; Ron Loewenthal; Denis M Schewe; Jacob Hochman; Lueder H Meyer; Dan Kaufman; Gunnar Cario; Angel Porgador; Shai Izraeli
Journal:  Blood       Date:  2015-04-20       Impact factor: 22.113

10.  Natural killer cell therapy in children with relapsed leukemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba; Guolian Kang; Kwan Gan; Christine Hartford; Brandon M Triplett; Mari Dallas; David Shook; Tanja Gruber; Ching-Hon Pui; Wing Leung
Journal:  Pediatr Blood Cancer       Date:  2015-04-30       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.